Synapse - Monica Fornier

Search Within

Monica Nancy Fornier

Results (158)

A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: Promising activity in metastatic pancreatic cancer

Meeting Abstract

Rathkopf, D.; Fornier, M.; Shah, M. A.; Kortmansky, J.; O'reilly, E.; Winkelmann, J.; Balzano, L.; Kelsen, D. P.; Schwartz, G. K.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

A prospective longitudinal study of the impact of adjuvant chemotherapy for breast cancer (BC) on older patients' functional status and quality of life

Meeting Abstract

Hurria, A.; Panageas, K.; Zuckerman, E.; Fornier, M.; D'Andrea, G.; Dang, C.; Moasser, M.; Robson, M.; Seidman, A.; Currie, V.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Increased dose-density (DD) is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC)

Meeting Abstract

Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C. H.; Panageas, K.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Serum HER-2/neu has clinical utility in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzamab-based therapies

Meeting Abstract

Cheli, C. Q.; Esteva, F. J.; Fritsche, H.; Fornier, M.; Slamon, D.; Thiel, R. P.; Lueftner, D.; Ghani, F.
Clinical Chemistry (2005)

Fulltext@MSK | Save

Dose-dense adjuvant chemotherapy for primary breast cancer

Journal Article

Fornier, M.; Norton, L.
Breast Cancer Research (2005)

Fulltext@MSK | Save

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Journal Article

Esteva, F. J.; Cheli, C. D.; Fritsche, H.; Fornier, M.; Slamon, D.; Thiel, R. P.; Luftner, D.; Ghani, F.
Breast Cancer Research (2005)

Fulltext@MSK | Save

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

Journal Article

Fornier, M. N.; Seidman, A. D.; Schwartz, M. K.; Ghani, F.; Thiel, R.; Norton, L.; Hudis, C.
Annals of Oncology (2005)

Fulltext@MSK | Save

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

Journal Article

Fornier, M. N.; Modi, S.; Panageas, K. S.; Norton, L.; Hudis, C.
Cancer (2005)

Fulltext@MSK | Save